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1. Introduction 
Thyroid hormones play a crucial role in the skeletal growth, peak bone mass acquisition and 
maintenance of bone mass. Abnormalities in hypothalamic–pituitary–thyroid axis in infancy 
and childhood have been shown to interfere with a normal linear growth and skeletal 
maturation. Hypothyroidism compromises normal bone formation and results in slowing of 
linear growth. Thyrotoxicosis leads to growth acceleration, diminution of bone mass and 
advance in bone age. Studies in animal models have demonstrated the importance of 
thyroid hormone signaling in the maintenance of bone mass in adulthood. Increased risk of 
fracture has been demonstrated in both hypothyroidism and hyperthyroidism. The thyroid 
hormone, 3,5,3’-triiodothyronine (T3), has long been considered to play a primordial role in 
the skeletal homeostasis. However, recent studies have shown that TSH acts as a direct 
regulator of bone remodeling, highlighting the importance of integrity of the hypothalamo-
pituitary-thyroid axis. 
This chapter will review our current understanding regarding the action of thyroid 
hormones on the bone development and maintenance of bone mass, under normal 
conditions and as a result of thyroid gland dysfunction. Mechanism of thyroid hormone 
action will be illustrated in relation to bone with the focus on the genetic regulation and the 
molecular interactions between thyroid hormones and skeletal cells. Clinical consequences 
of thyroid dysfunction on the growth and skeletal maturation will be detailed. We will 
review the published literature regarding BMD in hyperthyroid and hypothyroid patients 
including patients on medical therapy, as well as the influence of sex and menopause on the 
maintenance of bone mass. The impact of treatments for thyroid dysfunction on the bone 
mineral metabolism will be discussed.  
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2. Role of thyroid hormones in bone growth and metabolism 
Thyroid hormones are critical for the skeletal development and the bone maintenance. The 
thyroid hormone, 3,5,3’-triiodothyronine (T3), is responsible for major actions of thyroid 
hormones. T3 binds to nuclear receptors that regulate gene transcription via interaction with 
thyroid hormone response elements of specific genes (Sap et al., 1986; Weinberger et al., 
1986; Thompson et al., 1987). Recently, non-genomic actions of T3 and T4 have been 
described (Cheng et al., 2010). Local tissue availability of T3 seems to be regulated by type 2 
and 3 deiodinase (St Germain et al, 2009). The nuclear thyroid hormone receptors (TRs) are 
derived from the THRA and THRB genes coding for the TRα1 and β1-2 T3-binding 
isoforms, truncated isoforms ∆α1, ∆α2 and ∆β3, and a TRa2 non-T3-binding isoform of 
unknown function (Lazar et Chin et al, 1990; Lazar, 1993; Chassande et al, 1997; Williams, 
2000; Cheng et al, 2010). Expression of TRα1 and TRβ1 was described in growth plate 
chondrocytes, osteoblasts, and stromal cells of bone marrow (Williams et al, 1994; Abu et al, 
1997; Ballock et al, 1999; Bradley et al, 1992; Bassett et Williams, 2003; Siddiqi et al, 2002). 
Expression of TRα in the skeleton is higher than that of TRβ (Bookout et al, 2006; O’Shea et 
al, 2003). 
2.1. Thyroid hormone and bone development 
Studies on animal models have brought valuable insights into role of TRs in bone 
development and growth. Mice lacking TRβ or TRα1 did not display abnormalities in 
skeletal development (Forrest et al, 1996; Wikstrom et al, 1998). On the other hand, genetic 
disruption of both receptors (TRα1 and TRβ) led to delayed ossification and disorders in 
development of epiphyseal growth plates (EGPs; Gothe et al, 1999). Pax-8−/− mice, expressing 
all TR isoforms, but lacking the follicular cells producing T4 and T3 in the thyroid gland, 
displayed more severe abnormalities in bone development than mice KO for all TRs (TRα0/0, 
TRβ−/−) (Flamant et al, 2002). The authors concluded that the unliganded TRs (aporeceptors) 
on thyroid hormone responsive genes have repressor effects during bone development. In 
support of this, Pax-8−/−TRα0/0, but not Pax-8−/−TRβ−/−, compound mutants presented a partial 
rescue of the bone phenotype (O’Shea et Williams, 2002; Flamant et al, 2002). Another study 
was realized employing mice invalidated for TRα. These animals were euthyroid, but 
displayed a growth delay with abnormal bone development and ossification (Bassett et al 
2007a, 2007b; Gauthier et al, 1999, 2001; O’Shea 2003, 2005). Mice lacking all TRα isoforms 
presented a less severe impairment of bone development than TRα-/- mice, pointing to the 
role of non-T3 binding TRα isoforms (∆α1 and ∆α2) (Gauthier et al, 2001). On the other 
hand, mice with nonfunctional TRβ displayed augmentation in circulating thyroid hormone 
levels associated with dysregulation of hypothalamo-pituitary-thyroid axis. These animals 
had skeletal signs of hyperthyroidism, increased bone mineral deposition and acceleration 
of growth-plate maturation, resulting in a short adult body size (Bassett et al, 2007a; O’Shea 
et al, 2003). These findings suggested an increased skeletal response to T3 via TRα, which 
was consistent with the hypothesis that elevated circulating thyroid hormone levels in TRβ 
mutant mice result in an increased skeletal response to T3 via TRα (O’Shea et al, 2006). 
Recently, GC-1, thyroid hormone analogue targeting preferentially TRβ1 over TRα1, has 
 
Thyroid Disorders and Bone Mineral Homeostasis 253 
partially reverted skeletal development and maturation defects in hypothyroid rats (Freitas 
et al, 2005). This finding is suggestive of TRβ1 involvement in bone growth.  
Thyroid hormones regulate bone development also indirectly through the growth hormone 
(GH) and insulin-like growth factor-I (IGF-I) axis. Previously, it was demonstrated that T4 
enhanced the growth promoting effect of GH/IGF-I (Thorngren et Hansson, 1974) and could 
stimulate longitudinal bone growth in hypophysectomized rats (Thorngren et Hansson, 
1973; Ray et al, 1954). T3 was shown to interact with the thyroid hormone receptor - thyroid 
hormone responsive element complex (TR-TRE) in the GH promoter to regulate GH gene 
transcription (Glass et al, 1987; Koenig et al, 1987). However, GH without T3 did not 
promote the maturation (Ballock et Reddi, 1994) and organization (Lewinson et al, 1989) of 
growth plate chondrocytes and GH replacement could not rescue the impaired ossification 
in TRα and TRβ-null mice (Kindblom et al, 2001). In TRα1−/−β−/− mice, GH substitution 
reversed the growth phenotype, but not the defective ossification (Kindblom et al, 2001).  On 
the other hand, inactivation of GH or IGF-I receptors in mice was associated with delayed 
ossification (Liu et al, 1993; Sjogren et al, 2000). 
Overall, the literature data indicate importance of both TRs and GH-IGF-I axis in skeletal 
development. Other factors, such as the Indian Hedgehog (Ihh), parathyroid hormone-
related peptide (PTHrP), fibroblast growth factor receptor and Wnt--catenin signaling 
pathways, are implicated in this process (Barnard et al, 2005; O’Shea et al, 2005; Stevens et 
al, 2000, 2003; Wang et al, 2007). Further studies are warranted to clarify the exact 
mechanisms underlying the physiological regulation of bone development. 
2.2. Thyroid hormone and bone remodeling 
Literature evidence points to the critical importance of thyroid hormones in bone 
remodeling and maintenance. Adult euthyroid mice invalidated for TRα have reduced 
osteoclastic bone resorption and increased trabecular bone volume and mineralization 
(Bassett et al, 2007a, 2007b), indicating a critical role of TRα in T3 action in bone cells. On the 
other hand, increased osteoclastic bone resorption and severe osteoporosis were 
demonstrated in adult TRβ mutant mice, suggestive of thyroid hormone excess in TRα-
expressing skeletal cells (Bassett et al, 2007a, 2007b; Gauthier et al, 2001; O’Shea et al, 2006). 
The bone architecture and strength are maintained by a balanced process of remodeling, 
which involves recruitment of osteoclast and osteoblasts. T3 can induce differentiation and 
inhibits proliferation of osteoblastic cells. T3 was shown to promote production of IL-6, IL-8, 
IGF-I and its binding proteins IGFBP2-4 in bone marrow stromal cells and osteoblasts (Milne 
et al, 2001; Siddiqi et al, 1998), and to increase the expression of several bone-related genes, 
including osteocalcin, collagen type I, gelatinase B and collagenase 3 (Gouveia et al 2001; Milne 
et al 1998; Pereira 1999; Varga et al 1997; Williams et al 1994). T3 is implicated in 
chondrogenesis, angiogenesis, bone matrix formation and mineralization (Himeno et al, 2002; 
Makihira et al, 2003; Pereira et al, 1999). In primary cultures of growth plate chondrocytes, T3 
inhibits chondrocyte clonal expansion and cell proliferation, induces hypertrophic 
chondrocyte differentiation and promotes cartilage matrix mineralization (Robson et al, 2000).  
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Furthermore, T3 is involved in local signaling pathways by stimulating osteoblast responses 
to IGF1-I, PTH and fibroblast growth factors. T3 is a critical regulator of the Ihh - bone 
morphogenetic protein (BMP) – PTHrP feedback loop (Stevens et al, 2000). Hypothyroidism 
is marked by increased PTHrP expression and impaired hypertrophic chondrocyte 
differentiation (Stevens et al, 2000). In hyperthyroidism, reduced expression of PTHrP 
associated with augmentation of BMP enhances hypertrophic chondrocyte differentiation 
(Lassova et al, 2009; Stevens et al, 2000). It has also been shown that T3 regulates terminal 
differentiation of growth plate chondrocytes in part through controlling cell cycle 
progression at the G1/S restriction point (Ballock et al, 2000). T3 mediates osteoclastic bone 
resorption through activation of osteoblasts, which then release receptor activator for NF-κB 
ligand (RANKL), a member of the TNF cytokine family. RANKL is a ligand for 
osteoprotegerin, a cytokine that regulates osteoclastic differentiation, and functions as a key 
factor for osteoclast differentiation and activation by inhibiting osteoclasts apoptosis (Allain 
et al, 1992; Britto et al, 1994).  
Overall, T3 seems to enhance activity of osteoblasts by various mechanisms and signaling 
loops. Although the effects of thyrotoxicosis in adult bone are characterized by increased 
bone resorption, it is not known whether T3 acts directly in osteoclasts or whether effects on 
osteoclasts are secondary to the actions of T3 in osteoblasts. 
2.3. Role of TSH on bone 
Thyroid stimulating hormone (TSH) is a ligand hormone between hypothalamic-pituitary 
axis and the thyroid gland. TSH has long been recognized to act on the thyroid gland to 
control follicle development and thyroid hormone production and secretion. Beyond 
thyroid, TSH has also been shown to have additional effects on other tissues. TSH can exert 
a direct effect on bone metabolism independently of the peripheral thyroid hormone 
(thyroxine, T4, and triiodothyronine, T3) levels. This effect is mediated through the receptor 
for binding the thyroid-stimulating hormone (TSH-R), which is a pituitary G protein-
coupled transmembrane receptor. Its expression has been demonstrated on osteoblast and 
osteoclast precursors. The TSH-R haploinsufficient mice display osteoporosis and focal 
osteosclerosis and thyroid hormone replacement did not restore bone mass but corrected 
growth deficiency in these animals (Abe et al, 2003). It has been suggested that the effects of 
TSH on the skeleton are independent of thyroid hormone levels.  
In vitro and in vivo studies have provided evidence that TSH has negative effects on both 
osteoclasts and osteoblasts (Abe et al, 2003; Hase et al, 2006; Sun et al, 2006; Ma et al, 2011). 
TSH inhibits osteoclastogenesis by attenuating Janus N-terminal kinase (JNK) and NF-KB 
signaling. The osteoclast-inhibitory actions of TSH are partially mediated also through 
effects on tumor necrosis factor (TNF)-alpha production as it has been demonstrated in 
murine models (Abe et al, 2003). Mice lacking the TSHR present osteoporosis, early in 
embryogenesis, due to increased osteoclast formation (Abe et al, 2003; Hase et al 2006; Ma et 
al, 2009). These observations have not been confirmed in double-null mice of TSHR and 
TNF-alpha supporting thus the role of TNF-alpha in increased osteoclastogenesis (Abe et al, 
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2003; Hase et al 2006; Ma et al, 2009). Yamoah et al (2008) have recently described RANKL-
responsive elements on the TNF alpha gene providing new insights into regulation of TNF 
transcription in osteoclast formation. The role of TSH on RANKL remains controversial 
since the administration of the exogenous recombinant TSH in animal models and humans 
has been shown to increase and in other series to decrease RANKL serum levels (Martini et 
al, 2008; Sampath et al, 2007; Abe et al, 2003). Role of TSH in osteoblastogenesis seems to be 
mediated through attenuation of Wnt and VEGF signaling (Abe et al, 2003). Enhanced 
osteoblastogenesis in TSHR deficiency was found to be associated with increased expression 
of low-density lipoprotein receptor–like protein-5 and Flk-1 proteins (Abe et al, 2003). 
Expression of these receptors, but not that of osteoblastic transcription factors, was inhibited 
by rhTSH. Altogether, these observations suggest that TSH negatively modulates bone 
turnover, however, further research is warranted to explain in detail the regulatory 
pathways.  
3. Thyroid hormones and skeletal growth in infancy and adolescence 
In prepubertal children, the linear growth is controlled mainly by GH-IGF-I axis, with 
influence from glucocorticoids and thyroid hormones. Thyroid hormones were shown to 
play an essential role for normal onset of the childhood component of growth (Heyerdahl, 
1997). Role of the GH/IGF-I axis in the regulation of thyroid gland growth has recently been 
demonstrated (Boas et al, 2009). During pubertal period, sex steroids are important co-
regulators of skeletal growth. Age related consequences of thyroid dysfunction on bone 
development have largely been described. Nevertheless, the exact role of thyroid hormone 
in the peak bone mass acquisition during childhood and early adulthood is not well 
understood. The same is for the gender specific action of T3 in the developing skeleton 
(Gauthier et al, 1999). 
Euthyroid status is essential for normal skeletal development and linear growth. 
Generalized retardation in endochondral and intramembranous ossification associated with 
alterations in the EGPs, such as reduced thickness, disorganized columns of chondrocytes, 
and impaired differentiation of hypertrophic chondrocytes, have been reported in 
hypothyroid status during development (Lewinson et al, 1989; Stevens et al, 2000). The 
clinical consequences are reduced growth and skeletal abnormalities (Allain & McGregor, 
1993). Theodore Kocher was awarded the Nobel Prize in Medicine in 1909 for his 
description of consequences of thyroidectomy. He showed the impact of hypothyroidism on 
the child growth (Kocher, 1883). Hypothyroid children present with the growth retardation 
and disproportionately short limbs in relation to the trunk. Radiographic skeletal 
examination may reveal, depending on the age and onset of hypothyroidism, a delayed 
closure of the fontanelles, enlargement of pituitary fossa and epiphyseal dysgenesis. Reilly 
& Smyth have described in 1937 stippled appearance of epiphyses on X-ray films in 
hypothyroid children. The pathognomonic nature of these changes was later confirmed by 
Wilkis (Wilkis, 1941). Epiphyseal dysgenesis has been demonstrated in the ossification 
centers that normally ossify after the onset of the hypothyroid status. Delayed appearance of 
ossification centers and delayed bone age are also noted in hypothyroid children. BMD 
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seems to be also affected by a hypothyroid status during childhood. In one cross-sectional 
study, BMD was reported to be lower in prepubertal children with congenital 
hypothyroidism than in controls (Demartini et al, 2007). 
Treatment with thyroxine results in a period of rapid catch-up growth, although predicted 
final height based on midparental height calculations may not be achieved, particularly 
when hypothyroidism is prolonged (Rivkees et al, 1988). The LT4 replacement for 8 years in 
children with congenital hypothyroidism did not have a negative effect on BMD for the 
lumbar spine and the femoral site and on biochemical markers of bone turnover (Leger et al, 
1997). The results showed normal serum levels of calcium, phosphate, alkaline phosphatase, 
parathyroid hormone and 25-hydroxyvitamin D and did not demonstrate any relationship 
between BMD and L-T4 dosage or biochemical markers of bone formation. These findings 
were confirmed by other studies reporting no alterations of bone mass in adolescents and 
young adults with congenital hypothyroidism, treated from the neonatal period (Salerno et 
al, 2004, Demeester-Mirkine et al, 1990). 
On the other hand, thyroid hormone excess results in accelerated skeletal maturation, 
premature closure of the EGPs and subsequent decrease in longitudinal bone growth with a 
compromised final adult height (Allain & McGregor, 1993; O’Shea et al, 1993; Harvey et al, 
2002). In severe cases, hyperthyroidism during early childhood may also cause 
craniosynostosis due to premature fusion of the sutures of the skull (Segni et al 1999). Low 
bone density values and high bone resorption rates were demonstrated at diagnosis of 
hyperthyroidism in children and adolescents (Mora et al, 1999). Successful treatment of 
hyperthyroidism was shown to increase BMD in children and improve the conditions for 
the best obtainable peak bone mass (Mora et al, 1999). 
Consequences of syndrome of resistance to thyroid hormone (RTH) on the skeletal 
development have been described in literature. RTH results from dominant negative 
mutations in the carboxyl terminus of the thyroid hormone receptor β gene. The mutant 
receptors are transcriptionally impaired and inhibit thyroid hormone receptor action. RTH 
is characterized by phenotypic variability including skeletal manifestations (Weiss et 
Refetoff, 2000). Our current understanding is based mainly on the published case reports. 
Involvement of the skeleton can cause a short stature, advanced or delayed bone age, 
increased bone turnover, osteoporosis, fractures, craniofacial abnormalities and 
craniosynostosis. The clinical variability might be secondary to functional properties of 
mutant proteins and heterogeneity of cofactors mediating action of TR (Kvistad et al, 2004).  
4. Effects of thyroid dysfunction on bone turnover in adult bone 
4.1. Hypothyroidism 
Reduced bone turnover in hypothyroidism impairs bone formation and mineralization 
(Eriksen et al, 1986). Results of population studies indicate an increased fracture risk in 
hypothyroid individuals (Ahmed et al, 2006; Vestegaard et al 2002, 2005). The association 
between subclinical hypothyroidism and decreased BMD with increased fracture risk has 
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also been reported, but has not been confirmed by others (Lee et al, 2006, 2010; Bertoli et al, 
2002). Overall, the literature data have so far presented conflicting results. We will review 
the current literature and discuss changes in the bone metabolism, BMD and fracture risk in 
adult men and women with overt and subclinical hypothyroidism. 
4.1.1. Mineral metabolism in hypothyroidism 
Slight perturbations in some parameters of bone and mineral metabolism have been 
reported in hypothyroid patients. Minor abnormalities of calcium metabolism may exist 
with slightly elevated serum calcium, PTH and 1,25(OH)2 vitamin D, decreased level of 
alkaline phosphatase, decreased urinary calcium excretion and glomerular filtration rate. 
The exchangeable pool of calcium and its rate of turnover may be reduced, reflecting 
decreased bone formation and resorption. However, these changes seem not to be different, 
even during the treatment, in hypothyroid patients compared to euthyroid controls 
(Sabuncu et al, 2001). 
4.1.2. Overt hypothyroidism and skeletal changes 
Large population based studies identified an increased fracture risk in individuals with 
hypothyroidism (Vestegaard et al 2000; 2002). The first of these studies (Vestegaard et al, 
2000) analyzed 408 patients with primary hypothyroidism and found a temporary increase 
in fracture risk within the first 2 years after diagnosis, mainly in the age group >50 years, 
and was limited to the forearms. In the following study (Vestegaard, 2002), 4473 patients 
with autoimmune hypothyroidism (mean age, 66.1 +/- 17.3) were shown to present a 
significantly increased fracture risk up to 8 years prior to diagnosis with a peak around the 
time of diagnosis. The fracture risk was found to return to normal more than 5 years after its 
diagnosis. 
An increased fracture risk in hypothyroid patients is not probably due to modifications of 
bone density. There are no convincing literature data as to changes in bone architecture 
during hypothyroidism. Neuromuscular symptoms and impaired muscle energy 
metabolism could be responsible for bone changes in this population. Hypothyroid patients 
have been shown to display impaired neuromuscular response to exercise persisting even 
after restoration of euthyroid status (Caraccio et al, 2005). 
4.1.3. Subclinical hypothyroidism and skeletal changes 
Subclinical hypothyroidism is a relatively frequent clinical condition, particularly among 
aged population, characterized by a low-normal free T4 level and a slightly elevated TSH 
level. The prevalence of subclinical hypothyroidism has been reported between 3.9 and 6.5% 
(Hollowell et al, 2002; Huber et al, 2002) 
In Trosmo study, Grimnes et al. (2008) have demonstrated that, after multivariate 
adjustment, 25 out of 950 postmenopausal women with serum TSH above the 97.5 percentile 
had significantly higher BMD at the femoral neck than women with serum TSH in the 
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normal range. However, there was no association between TSH and BMD, and serum TSH 
as a continuous variable had no effect on BMD. 
Bone quality was studied by Nagata et al. using quantitative ultrasound in postmenopausal 
women with subclinical hypothyroidism. The results demonstrated that calcaneo osteo sono 
assessment indices of right feet measured by ultrasound bone densitometer decreased 
according to the increase in TSH concentration. The authors have suggested that 
hypothyroidism affects bone structure (Nagata et al, 2007). 
4.2. Hyperthyroidism 
Hyperthyroid patients present with an increased bone turnover and a risk for osteoporosis. 
The activity of osteoblasts and osteoclasts are increased, the latter predominates favoring 
resorption, negative balance of calcium, and bone loss (Melsen & Mosekilde, 1977; 
Mosekilde et al, 1990). Thyrotoxicosis in adults is a recognized cause of high-bone-turnover 
osteoporosis. Reduced bone mineral density was noted in hyperthyroid patients with an 
increased susceptibility to fragility fracture (Mosekilde et al, 1990; Vestergaard et al, 2002, 
2005). 
In both, clinical and subclinical hyperthyroidism, elevation of markers of bone turnover and 
decreased BMD have been reported (Kumeda et al, 2000; Heemstra et al, 2006; Lee et al, 
2006). Previous studies that investigated impact of thyroid dysfunction on BMD and 
fracture risk did not provide conclusive results. Recently published population studies 
indicate association of endogenous subclinical hyperthyroidism with an increased fracture 
risk (Bauer et al, 2001; Jamal et al, 2005; Vadiveloo et al, 2011). Consequences of the 
hyperthyroid status (overt and subclinical) on bone turnover, BMD and fracture risk will be 
discussed and compared with the data in healthy population. 
4.2.1. Mineral metabolism in hyperthyroidism 
Hyperthyroidism is associated with impaired mineral metabolism. Increased serum calcium 
levels have been reported in up to 27% of hyperthyroid patients (Begic-Karup et al, 2001), 
but severe and symptomatic hypercalcemia is rare. Concentrations of serum alkaline 
phosphatase and osteocalcin are also frequently elevated. These findings are reminiscent of 
those in primary hyperparathyroidism, however, serum parathyroid hormone is mostly 
low-normal (Iqbal et al, 2003). True primary hyperparathyroidism and thyrotoxicosis may 
coexist (Beus & Stack, 2004; Wagner et al, 1999). Decreased plasma 25-
hydroxycholecalciferol levels observed in hyperthyroidism could participate to the lower 
intestinal absorption of calcium and osteopenia in these patients (Mohan et al, 2004). Bone 
resorption markers, urinary pyridinoline and deoxypyridinoline, are increased 7-8 times 
more than in age and sex matched controls (Kraenzlin et al, 2008). Furthermore, 
hyperthyroid patients display a greater increase in urinary pyridinoline cross-links than that 
in serum markers of bone formation (osteocalcin, bone-specific alkaline phosphatase) 
(Akalin et al, 2002; Kisakol et al, 2003). Altogether, an increased bone turnover in these 
patients is in favor of osteoclastic bone resorption. 
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After initiation of anti-thyroid treatment, biochemical markers of bone resorption, such as 
urinary hydroxyproline, serum pyridinoline, serum deoxypiridinoline cross-links, have 
been found to fall, with a subsequent rise of the bone formation markers (Mosekilde et al 
1990; Siddiqi et al, 1997; Garnero et al, 1994). Elevation of serum PTH has been reported in 
some patients with severe thyrotoxicosis under anti-thyroid treatment (Pantazi et al, 2000). 
This rise in PTH was suggested to play a role in inducing some temporal changes in mineral 
metabolism and participate to the reversal of the catabolic bone status of hyperthyroidism to 
anabolic. Furthermore, another study found that in hyperthyroidism, despite normal or high 
IGF-I levels, IGF-I bioactivity is reduced, probably because of high levels of IGF-binding 
protein-1 (Miell et al, 1993). Treatment of thyrotoxicosis reverses this abnormality. The rise 
in IGF-I bioactivity may therefore have a positive effect on the bone metabolism. 
4.2.2. Overt hyperthyroidism and skeletal changes 
Pathological skeletal changes, including osteopenia and osteoporosis, with higher 
incidence of fracture rates have been reported in hyperthyroid patients. Accordingly, 
hyperthyroidism was found 2.5-fold more often in postmenopausal women presenting 
with hip fracture than in controls. Among postmenopausal women, risk of hip fracture 
was significantly higher in patients with overt untreated hyperthyroidism and a history of 
past hyperthyroidism (Wejda et al, 1995). These findings were confirmed by a prospective 
follow-up study realized in 9516 Caucasian women, 65 years of age or older (Cummings 
et al, 1995). The authors demonstrated a higher risk of hip fracture among women who 
had previous hyperthyroidism. Another study reported that the prevalence of all types of 
fractures in patients with a history of thyroid disease was not different from that of 
control subjects.  
However, women with a history of hyperthyroidism or thyroid cancer appeared to have 
their first fracture earlier than women without thyroid disease (Solomon et al, 1993). Median 
lumbar BMD in patients with thyrotoxicosis was shown to be 12.6% lower than that of 
normal individuals before the initiation of treatment (Krolner et al, 1983). Decreased BMD in 
hyperthyroid patients was demonstrated particularly in areas consisting of cortical bone. 
The risk of hip fracture increased significantly with age at diagnosis of hyperthyroidism 
(Campos-Pastor et al, 1993; Udayakmar et al, 2006; Vestergaard et al, 2002, 2005). The 
etiology of hyperthyroidism is not believed to play a role in the severity of hyperthyroid 
bone disease (Jodar et al, 1997). 
A recent meta-analysis (Vestergaard et al, 2005) evaluated data regarding BMD and fracture 
risk in 20 (962 patients) and 5 publications, respectively (62 830 patients and controls). The 
results showed that patients with hyperthyroidism have a significantly decreased BMD. 
These values were lower in untreated patients compared to those under treatment, 
particularly for the lumbar spine (-0.83 vs. -0.27 Z-score) and the femoral site (-0.75 vs. -0.15 
Z-score). The risk of hip fracture at the moment of diagnosis of hyperthyroidism was 1.6 
(95% CI 0.7 to 3.4), and the value of BMD alone was associated with a risk of hip fracture 
corresponding to 1.2 (95% CI 0.9-1.5).  
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Decreased bone density in hyperthyroid patients tended to normalize under treatment 
(Wejda et al, 1995, Jodar et al, 1997). The improvement of BMD was noted even though no 
other specific anti-osteoporotic measures were introduced. The type of treatment of 
hyperthyroidism, iodine 131 or anti-thyroid drugs was not shown to alter the fracture risk 
(Vestergaard et al, 2005). 
4.2.3. Subclinical hyperthyroidism and skeletal changes 
Subclinical hyperthyroidism is defined as subnormal serum TSH with normal serum free 
thyroid hormones without signs or symptoms of thyrotoxicosis. Its prevalence in the U.S. 
population has been reported 0.7% (Hollowell et al, 2002). By definition, such patients 
should not have any clinical abnormalities associated with thyrotoxicosis (Biondi et al, 
2005). However, a reduced bone mass was reported among postmenopausal patients (Bauer 
et al 2001). These observations could thus have a broader impact on the healthcare systems, 
as the subclinical hyperthyroidism is more frequent than overt thyrotoxicosis (Hollowell et 
al, 2002). Improvement of bone mineral density was shown in postmenopausal women with 
subclinical hyperthyroidism after normalization of their thyroid function (Faber et al, 1998). 
These data would justify indications of treatment in the older population. However, the 
risk/benefit ratio needs to be demonstrated by long-term, randomized studies. 
On the other hand, the bone mineral density of the lumbar spine, femoral neck and the 
midshaft of the radius were not significantly decreased in premenopausal women (Foldes et 
al, 1993). The impact of subclinical hyperthyroidism in men is less known. A recent work 
suggests that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men (Kim et al, 2010). 
5. Impact of thyroid hormone treatment on bone metabolism 
Effects of thyroid replacement therapy or thyroid suppressive therapy on bone mineral 
density (BMD) are controversial. Results of previous studies are confounded by differences 
in study design, insufficient prospective data and small numbers of subjects. In the 
population study by Vestergaard et al (2005), the use of anti-thyroid drugs was associated 
with a significantly reduced fracture risk, no effect of levothyroxine on fracture risk was 
observed. No influence of L-thyroxine therapy on BMD was reported in young adults with 
congenital hypothyroidism (Salerno et al, 2004). Recently published population based case-
control study has demonstrated a significantly increased fracture risk in adults over 70 years 
treated by levothyroxine (Turner et al, 2011). Publications on the association between the 
thyroid replacement and suppressive treatments and the bone mineral metabolism will be 
discussed. 
5.1. Thyroid hormone replacement therapy 
The objective of thyroid hormone replacement therapy is to normalize TSH levels. Some 
authors have suggested that treatment with levothyroxine may cause long-term 
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osteoporosis, but there is no evidence to support this theory, and studies have shown no 
difference in bone density or fracture risk in patients undergoing treatment.  
Previously, the effects of thyroid hormone treatment upon lumbar spine BMD were studied 
in a consecutive series of patients with myxedema. Patients with myxoedema did not differ 
from normal individuals as regards initial lumbar BMD, but levothyroxine-treatment caused 
a significant reduction in this variable. The median decrease in lumbar BMC after 1 year was 
8.9% (95% confidence limits 1.5-15.4%, P less than 0.05). This loss of bone might be 
attributed to an inappropriate increase in bone turnover in the euthyroid status (Krolner et 
al, 1983). Accelerated bone turnover was shown to occur in women with subclinical 
hypothyroidism during replacement L-T4 treatment and normal TSH levels (Meier et al, 
2004; Tarraga Lopez et al, 2011). In these women, bone loss was attributed to an adaptive 
mechanism on decreased bone turnover in pre-existent hypothyroidism. Finally, a long-term 
L-T4 treatment in children and adolescents with congenital hypothyroidism, diffuse goiter 
or with chronic lymphocytic thyroiditis did not affect BMD nor had a negative effect on the 
attainment of peak bone mass (Kooh et al, 1996; Saggese et al, 1996; Tumer et al, 1999). These 
results suggest that careful regulation of thyroid replacement is critical. Significant effects of 
prolonged L-T4-replacement therapy on bone tissue in patients with congenital 
hypothyroidism can be avoided by careful monitoring of serum TSH and adjustment of 
doses of L-T4 (Salerno et al, 2004). 
5.2. Thyroid hormone suppressive therapy 
Treatment with thyroid hormones with the objective to suppress TSH levels is used for 
example after surgery and radioiodine in differentiated thyroid carcinomas. The patients are 
maintained in subclinical hyperthyroidism, a condition associated with increased bone 
turnover.  
Previous studies indicated that adults receiving high doses of L-T4-replacement therapy 
may be at risk of excessive bone loss. Reduction in BMD was observed after exogenous 
administration of high L-T4 doses used to fully suppress TSH in cases of thyroid cancer, 
goiters or nodules. Further, a review of cross-sectional and prospective studies examining 
the effect of thyroid hormone suppression on skeletal integrity in adults showed neither 
significant negative effect nor a decrease in BMD (Greenspan et al, 1990). Conflicting results 
were reported also in children. A significant reduction in peripheral BMD was found in 
children and adolescents receiving suppressive doses of L-T4 treatment for endemic goiter, 
Hashimoto’s thyroiditis or thyroid cancer (Radetti et al, 1993). 
More recently, suppression of TSH in hyperthyroidism or after thyroid hormone treatment 
has been shown to result in decrease in BMD and increase in fracture risk in 
postmenopausal women (Vestergaard et al, 2000; Bauer et al, 2001; Jamal et al, 2005; Kim et 
al, 2006). Similar results have been demonstrated in premenopausal women and men by 
Karner et al (2005).  Recently realized systematic reviews analyzing effects of subclinical 
hyperthyroidism showed that postmenopausal women with subclinical hyperthyroidism 
may present an increased risk, whereas no increased risk has been demonstrated in men and 
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premenopausal women (Quan et al, 2002; Heemstra et al, 2006). However, both reviews 
found methodological differences between different studies, making a structured meta-
analysis impossible. Lately, a randomized prospective controlled trial has shown significant 
adverse effects of TSH suppressive therapy on BMD in women ≥ 50 years of age (Sugitani et 
Fujimoto, 2011). However, the results have not been adjusted for confounding factors, such 
as menopause status, dietary calcium, vitamin D intake, and smoking.  
Overall, literature data enhance the hypothesis that low TSH levels may have a deleterious 
effect on bone homeostasis. Nevertheless, the exact relationship between subclinical 
hyperthyroidism and osteoporosis remains to be explained. 
6. TSH as a metabolic regulator 
We previously discussed (see paragraph 1.2) the role of TSH in the control of bone 
remodeling in animal models (Abe E, Marians RC et al, 2003). Systemic administration of 
TSH to ovariectomised rats has been shown to prevent bone loss and restore bone mass 
(Sampath et al, 2007; Sun et al, 2008) have demonstrated that intermittent administration of 
exogenous TSH in ovariectomised rats and mice have anti-resorptive effects. Recent findings 
indicate that TSH might play a crucial role in bone turnover in humans. Bone loss has been 
shown in women with polymorphism in the TSHR gene (Onigata et al, 2005). 
There is a growing body of evidence that variations of TSH even in its reference range may 
influence BMD. A higher BMD has been reported in postmenopausal women with TSH 
within the physiological range comparing to these with the low level of TSH (Baqi et al, 
2010). Clinical observations show that patients with subclinical hyperthyroidism and normal 
circulating thyroid hormone levels display osteoporotic changes (De Menis et al, 1992; 
Kisakol et al, 2003). Strong correlation between serum TSH and bone status has been 
demonstrated in postmenopausal women (Bauer et al, 2001; Morris et al, 2007). Based on 
these findings it has been suggested that it is the suppressed TSH rather than the elevated 
thyroid hormones that exert a deleterious effect on bone density. In a recent observational 
study, low-normal TSH values were shown to be associated with high prevalence of 
vertebral fractures in women with post-menopausal osteoporosis or osteopenia, even after 
correction for age, BMD, BMI and serum free-thyroxine values (Mazziotti et al, 2010). Svare 
et al, 2009, in a cross-sectional, population-based study, analyzed 5778 women without and 
944 with self-reported thyroid disease aged >40 years. Women with the TSH level <0.50 
mU/l had lower forearm BMD than the reference group and the prevalence of osteoporosis 
was higher in women who reported hyperthyroidism than in women without self-reported 
thyroid disease. Finally, Kim et al, 2010 investigated the association between serum 
thyrotropin (TSH) concentration and bone mineral density (BMD) in 1478 healthy euthyroid 
men in a cross-sectional community based survey. Lumbar spine BMD and femoral neck 
BMD were shown to increase with TSH level after adjustment for age, weight and height. 
The odds of lower BMD were significantly increased in subjects with low-normal TSH, 
when compared to high-normal TSH after adjustment for confounding factors. These results 
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suggested that a serum TSH concentration at the lower end of the reference range may be 
associated with low BMD in men.  
The role of TSH on bone metabolism has also been analyzed through markers of bone 
metabolism after administration of recombinant TSH (rhTSH). TSH has been demonstrated 
to activate directly osteoblasts according to the increased levels of N-terminal propeptide of 
type I procollagen (PINP) (Martini et al, 2008). Others showed that TSH promotes the 
production and activity of alkaline phosphatase and of osteocalcin (Sampath et al, 2007; Abe 
et al, 2003), while some studies found inhibition of osteoblast differentiation induced by the 
administration of TSH (Abe et al, 2003). These finding suggested that TSH may enhance the 
differentiation of osteoblasts precursors.   
Clinically, it has been found that the administration of exogenous TSH may have 
antiresorptive effects of TSH on bone turnover.  In women monitored for thyroid carcinoma, 
a short-term stimulation with rhTSH had inhibitory effect on bone resorption. Acute 
administration of rhTSH in thyroidectomised postmenopausal women with suppressed 
endogenous serum TSH resulted in diminution in serum C-telopeptides of type-1 collagen 
and increase in bone alkaline phosphatase (Mazziotti et al., 2005). A transient inhibition of 
bone resorption and increase in osteoblastic activity, measured by markers of bone 
metabolism, after acute TSH administration was demonstrated also by other studies (Karga 
et al, 2010; Iakovou et al, 2010; Martini et al, 2008).  
Overall, these data constitute the evidence for relationship between TSH and a change in 
bone mass in humans. 
7. Bone effects of thyroid hormone analogues 
Synthetic analogues of thyroid hormones display tissue-specific actions (Baxter and Webb 
2009). They have been developed for their lipid lowering activity by preferential activation 
of the TRβ1 isoform in the liver while sparing the TRα1 mediated cardiac effects (Angelin & 
Rudling, 2010; Pramfalk et al., 2010; Webb, 2010). Previous animal and human studies have 
demonstrated that thyromimetics can influence bone metabolism. Skeletal effects of thyroid 
hormone analogues recently reported in literature on cell lines, animal models and humans 
are summarized in Table 1. 
Previously studied selective thyromimetic, tiratricol (3,5,3’-triiodothyroacetic acid; Triac) 
was shown to enhance skeletal metabolic activity (Sherman, et al 1997) and to produce 
adverse effects on bone metabolism (Alvarez et al 2004; Brenta et al 2003; Kawaguchi et al 
1994a, 1994b). DITPA, 3,5-diiodothyropropionic acid, has a higher affinity for the TRβ 
compared to the TRα. Administration of DITPA to humans for 24 weeks was associated 
with a significant rise in serum osteocalcin, N-telopeptide, and deoxypyridinoline levels, 
indicating an increased bone turnover (Ladenson el al 2010b). GC-1, [3,5-dimethyl-4-(4′-
hydroxy-3′isopropylbenzyl)-phenoxy acetic acid],  binds TRβ1 with the same affinity as T3, 
but TRα1 with a 10-fold lower affinity (Scanlan, 2010). Bone sparing effects in adult female 
rats have been observed after treatment by GC-1 for 64 days (Freitas et al, 2003). In another     
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Thyromimetic Study Design Skeletal effects Reference 
Tiratricol 
(Triac) 
Cultured neonatal 
mouse calvariae: Triac 
vs. T3 
More potent stimulation of  
resorption and less potent 
stimulation of formation vs. 
T3 
Kawaguchi 
1994a 
Tiratricol 
(Triac) 
Cultured fetal rat long 
bones and neonatal 
mouse calvariae; Triac 
vs. T3 
Equal or greater stimulation of 
bone resorption by Triac than 
T3 
Kawaguchi 
1994b 
Tiratricol 
(Triac) 
Rats; Triac vs. T3 Greater increase in beta-CTX 
levels, no alteration of BMD 
Alvarez         
2004 
Tiratricol 
(Triac) 
Randomized clinical 
trial (2 months); 
athyreotic patients: 
Triac vs. L-T4  
Increased serum osteocalcin 
and urinary excretion of 
calcium and pyridinium cross-
links 
Sherman       
1997 
Tiratricol 
(Triac) 
Randomized clinical 
trial (11 months); 
euthyroid goitrous 
women: 
Triac vs. L-T4  
Significant increase in serum 
deoxypyridinoline and 
significant decrease in hip 
bone density, but ns compared 
to L-T4;  
Brenta           
2003 
DITPA 
 
Prospective, controlled, 
double-blind clinical 
trial (24 weeks):                 
DITPA vs. placebo 
Increase in serum osteocalcin,  
N-telopeptide and 
deoxypyridinoline 
Ladenson      
2010b 
Sobetirome 
(GC-1)  
Rat and mouse               
osteoblast-like cells  
Induction of differentiation 
and activity of osteoblasts 
Beber             
2009 
Sobetirome 
(GC-1)  
 
Female adult Wistar 
rats;  study groups (64 
days):                 
GC-1; T3 ; control 
No effects on BMD in L2-L5, 
femur, and tibia; no changes in 
histomorphometric 
parameters of the femur 
Freitas           
2003 
Sobetirome 
(GC-1)  
 
21-day old female 
hypothyroid rats, 
treatment for 5 weeks: 
GC-1 vs. placebo  
Induction of ossification,             
HC differentiation, expression 
of collagen II and X mRNA, 
increase in EGP thickness 
Freitas           
2005 
Eprotirome 
(KB2115) 
 
Randomized, double-
blind, multicenter 12-
week clinical trial:             
Eprotirome vs. placebo  
No changes in b-ALP and type 
I collagen breakdown product;   
ns increase in PINP  
Ladenson      
2010a 
Table 1. Skeletal effects of thyroid hormone analogues: b-ALP – bone alcalic phosphatase; BMD - 
bone mineral density; EGP - epiphyseal growth plate; HC – hypertrophic chondrocytes; ns – non 
significant; PINP - procollagen type I N-terminal propeptide 
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study, partial reversion of the skeletal development and maturation defects has been shown 
in hypothyroid rats after 5 week therapy by GC-1 (Freitas et al 2005). Eprotirome, (KB2115), 
3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic 
acid, displays a higher affinity for TRβ1 isoform with hepatic uptake (Berkenstam 2008). 
Administration of eprotirome to humans for 12 weeks has not been associated with 
unfavorable bone effects (Ladenson et al 2010a). 
Altogether the data are consistent with potentially adverse skeletal effects of thyroid 
hormone analogues. However, no conclusive evidence can be drawn and further 
investigations would be justified to establish an accurate benefice/risk ratio before their 
clinical use. 
8. Conclusion 
The last decades have seen an increasing interest in the action of thyroid hormones in bone 
mineral homeostasis. In vivo and in vitro studies in cell lines as well as animal models have 
demonstrated a critical role of thyroid hormones, TSH and their receptors in the skeletal 
growth and its maintenance. However, many of the molecular mechanisms of thyroid 
hormone action remain still poorly defined.  
Clinical studies, consistently with animal data, indicate a close association between thyroid 
status and bone metabolism. Thyrotoxicosis results in an increased bone turnover, 
osteoporosis and a risk of fragility fracture. Thyroid hormone deficiency decreases bone 
turnover with a subsequent risk of bone fragility. Exogenous administration of suppressive 
doses of thyroxine was shown to negatively influences BMD and bone turnover. In future, 
prospective studies a prolonged time of observation will be necessary, as well as to increase 
the number of studied patients, in order to better assess the relative risk of osteoporosis in 
patients undergoing TSH-suppressive treatment. Another question that remains to be 
answered is if there is a benefit from treatment of subclinical thyroid disease on skeletal 
health.  
Finally, thyroid hormone analogues represent a promising therapeutic option for their lipid 
lowering activity. Nevertheless, literature data suggest their potentially adverse skeletal 
effects. No conclusive evidence can be drawn and further investigations would be justified 
to establish an accurate benefice/risk ratio before their clinical use. 
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